Clinical Trial Update: Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors [Phase 2]

View source ↗

Summary

A Phase 2 trial of selinexor in patients with myelofibrosis refractory or intolerant to JAK1/2 inhibitors was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: University of Utah | Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Status: TERMINATED | Results posted: 2024-10-09